1.Induction of Immune Tolerance after Transplantation.
The Journal of the Korean Society for Transplantation 1998;12(2):145-150
No abstract available.
Immune Tolerance*
2.Dendritic cells and transplantation immune tolerance--review.
Hui ZENG ; Guang-Sheng HE ; De-Pei WU
Journal of Experimental Hematology 2006;14(4):849-852
Dendritic cells (DC) play an important roles in the maintenance of central immune tolerance and peripheral immune tolerance. DC can be involved in formation of autoimmune tolerance by many mechanisms and demonstrate strong plasticity, so that DC become hot issue in the research of transplantation tolerance recently. In this article the DC typing and its role, the indirect pathway of DC-inducing immune tolerance, the F1t3L and apoptotic cell role, the modified DC by genetic engineering and the immune inhibitors were summarized.
Dendritic Cells
;
immunology
;
Humans
;
Immune Tolerance
;
Transplantation Tolerance
;
immunology
3.Oral Tolerance: Not Simple But more Complex.
Yeonseok CHUNG ; Chang Yuil KANG
Immune Network 2003;3(3):169-175
The intestinal immune system can discriminate between harmful and unharmful antigens and do not provoke productive immunity to unharmful antigen. Thus oral administration of antigen is one of classical methods for inducing antigen-specific immune tolerance in the periphery. Furthermore, oral tolerance has been investigated for the treatment of autoimmune disorders in human clinical trials. However, the detail mechanism of oral tolerance and contributing factors are not defined clearly at this time. Recent studies demonstrate unique types of immune cell that suppressing immune response, such as regulatory T cell and tolerogenic dendritic cell. This article reviews the factors involved in oral tolerance and discusses our current understanding base on the recent literatures and our works.
Administration, Oral
;
Dendritic Cells
;
Humans
;
Immune System
;
Immune Tolerance
4.Immune Tolerance by Induced Regulatory T Cells in Asthma.
Allergy, Asthma & Immunology Research 2012;4(3):113-115
No abstract available.
Asthma
;
Immune Tolerance
;
T-Lymphocytes, Regulatory
5.Nonalcoholic fatty liver disease and immune disturbance.
Lan WANG ; You-ming LI ; Fu-chu HE ; Ying JIANG
Chinese Journal of Hepatology 2008;16(11):870-871
7.Progress in regulatory T cells research.
Journal of Zhejiang University. Medical sciences 2006;35(5):568-572
Regulatory T cells (Treg) are functionally mature T cell subpopulations which are key players of maintaining the balance of immunological defense system. Treg can proliferate in vivo or in vitro by antigen specific way or non-antigen specific way, and actively control the properties of other immune cells by suppressing their functional activity and their proliferation as well.
Humans
;
Immune Tolerance
;
T-Lymphocytes, Regulatory
;
immunology
8.Role of Regulatory Cells in Oral Tolerance.
Marcin WAWRZYNIAK ; Liam O'MAHONY ; Mübeccel AKDIS
Allergy, Asthma & Immunology Research 2017;9(2):107-115
The immune system is continuously exposed to great amounts of different antigens from both food and intestinal microbes. Immune tolerance to these antigens is very important for intestinal and systemic immune homeostasis. Oral tolerance is a specific type of peripheral tolerance induced by exposure to antigen via the oral route. Investigations on the role of intestinal immune system in preventing hypersensitivity reactions to innocuous dietary and microbial antigens have been intensively performed during the last 2 decades. In this review article, we discuss how food allergens are recognized by the intestinal immune system and draw attention to the role of regulatory T (Treg) and B (Breg) cells in the establishment of oral tolerance and tolerogenic features of intestinal dendritic cells. We also emphasize the potential role of tonsils in oral tolerance induction because of their anatomical location, cellular composition, and possible usage to develop novel ways of specific immunotherapy for the treatment of allergic diseases.
Allergens
;
Dendritic Cells
;
Food Hypersensitivity
;
Homeostasis
;
Hypersensitivity
;
Immune System
;
Immune Tolerance
;
Immunotherapy
;
Palatine Tonsil
;
Peripheral Tolerance
9.Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center.
Ki Young YOO ; Sang Chun JOO ; Yong Mook CHOI
Blood Research 2016;51(1):37-43
BACKGROUND: Immune tolerance induction (ITI) can reduce inhibitors against factor VIII concentrates by 70-80%. In this study, we elucidated the characteristics of inhibitors and attempted to determine the proper indications and timing for ITI. METHODS: Subjects included hemophilia A patients registered at the Korea Hemophilia Foundation from 1991 through 2014. Inhibitors were classified as persistent and transient. Patients were classified into groups according to peak inhibitor titer: low (<2 BU/mL), moderate (2 to <5 BU/mL), high (5 to <10 BU/mL), and very high titer (≥10 BU/mL). RESULTS: Overall, 350 (21.4%) of 1,634 hemophilia A patients developed inhibitors at least once. Of these, 100 (6.1%) and 250 (15.3%) patients developed persistent and transient inhibitors, respectively. For transient inhibitors, the median peak titer was 1.0 BU/mL, persistent for median of 11.0 months (10.0, 8.0, 13.0, and 19.0 months in the low, moderate, high, and very high titer transient inhibitor groups, respectively). Overall, 95.8% (215), 72.2% (17), 52.4% (21), and 21.7% (97) of patients in the low, moderate, high, and very high titer groups became inhibitor-negative spontaneously, without ITI. CONCLUSION: Given the spontaneous disappearance of inhibitors and high cost of ITI, it is worthwhile to postpone ITI for 11 months unless the peak inhibitor titer is greater than 10 BU/mL.
Factor VIII
;
Hemophilia A*
;
Humans
;
Immune Tolerance
;
Korea
;
Longitudinal Studies
10.Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease.
Ming-Juan LIU ; Wen-Rong HUANG ; Li YU
Journal of Experimental Hematology 2015;23(2):596-600
Invasive fungal disease (IFD) causes a high morbidity and mortality in patients with hematological malignancies. Reactivation of IFD after chemotherapy or hematopoietic stem cell transplantation (HSCT) is very common and associated with poor prognosis. Secondary antifungal prophylaxis (SAP) is effective in preventing IFD recurrence. With effective SAP, a history of IFD is not an absolute contraindication to allogeneic HSCT or continuation of high-dose chemotherapy. In recent years, a variety of antifungal drugs such as voriconazole, itraconazole, AmB and caspofungin have been found to be effective for SAP. However, its management during granulocytopenia and immunosuppression remains challenging. This review summarizes the current status of SAP in patients with hematological malignancies.
Antifungal Agents
;
Hematologic Neoplasms
;
Humans
;
Immune Tolerance
;
Immunosuppression
;
Mycoses